Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial.

Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA, Han R, Ball S, Coleman C, Lo E, Wohlfahrt A, Sury M and 4 more

Show all authors

Yin M, Yu Z, Zak A, Gravallese EM

Arthritis & rheumatology (Hoboken, N.J.)14 Jul 2017Cited by 30 (Europe PMC)

PMID28544807DOI10.1002/art.40156PepBankPUB-28544807

Source link PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with rheumatoid arthritis controlled by TNF inhibitors, teriparatide did not significantly change erosion volume versus wait-list control.
In plain wordsIn patients with controlled rheumatoid arthritis, teriparatide did not significantly change erosion volume versus wait-list control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeErosion volume
Study
n = 24
Comparator
Wait-list control
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Measurements
Median change in erosion volume
−0.4 mm3
teriparatide
IQR of change in erosion volume
−34.5 to 29.6 mm3
teriparatide
Median change in erosion volume
9.1 mm3
wait-list control
IQR of change in erosion volume
−29.6 to 26.4 mm3
wait-list control
Source sentences
Summary
After 52 weeks, the median change in erosion volume in the teriparatide group was -0.4 mm³ (interquartile range [IQR] -34.5, 29.6) and did not differ significantly from that in controls (median change +9.1 mm³ [IQR -29.6, 26.4]) (P = 0.28).
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized controlled trial in 24 patients with erosive RA, osteopenia, and disease activity controlled by TNFi treatment for at least 3 months.
Summary · context
Half were randomized to receive teriparatide for 1 year and the others constituted a wait-list control group.
Report a problemFND-2854480701
02HumanRandomized controlled trialEfficacy outcome
In patients with controlled rheumatoid arthritis, radius erosion volume change did not differ significantly between teriparatide and control.
In plain wordsIn patients with controlled rheumatoid arthritis, radius erosion volume change did not differ significantly between teriparatide and control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeRadius erosion volume
Study
n = 24
Comparator
Wait-list control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
No significant difference in change in erosion volume was noted at the radius, ulna, or metacarpophalangeal joints.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized controlled trial in 24 patients with erosive RA, osteopenia, and disease activity controlled by TNFi treatment for at least 3 months.
Summary · context
Half were randomized to receive teriparatide for 1 year and the others constituted a wait-list control group.
Report a problemFND-2854480702
03HumanRandomized controlled trialEfficacy outcome
In patients with controlled rheumatoid arthritis, ulna erosion volume change did not differ significantly between teriparatide and control.
In plain wordsIn patients with controlled rheumatoid arthritis, ulna erosion volume change did not differ significantly between teriparatide and control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeUlna erosion volume
Study
n = 24
Comparator
Wait-list control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
No significant difference in change in erosion volume was noted at the radius, ulna, or metacarpophalangeal joints.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized controlled trial in 24 patients with erosive RA, osteopenia, and disease activity controlled by TNFi treatment for at least 3 months.
Summary · context
Half were randomized to receive teriparatide for 1 year and the others constituted a wait-list control group.
Report a problemFND-2854480703
04HumanRandomized controlled trialEfficacy outcome
In patients with controlled rheumatoid arthritis, metacarpophalangeal erosion volume change did not differ significantly between teriparatide and control.
In plain wordsIn patients with controlled rheumatoid arthritis, finger joint erosion volume change did not differ significantly between teriparatide and control.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeMetacarpophalangeal erosion volume
Study
n = 24
Comparator
Wait-list control
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
No significant difference in change in erosion volume was noted at the radius, ulna, or metacarpophalangeal joints.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized controlled trial in 24 patients with erosive RA, osteopenia, and disease activity controlled by TNFi treatment for at least 3 months.
Summary · context
Half were randomized to receive teriparatide for 1 year and the others constituted a wait-list control group.
Report a problemFND-2854480704
05HumanRandomized controlled trialEfficacy outcome
In patients with controlled rheumatoid arthritis, femoral neck BMD improved in the teriparatide group.
In plain wordsIn patients with controlled rheumatoid arthritis, femoral neck bone density improved during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseFemoral neck BMD
Study
n = 12
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
Bone mineral density improved at the femoral neck and lumbar spine in the teriparatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized controlled trial in 24 patients with erosive RA, osteopenia, and disease activity controlled by TNFi treatment for at least 3 months.
Summary · context
Half were randomized to receive teriparatide for 1 year and the others constituted a wait-list control group.
Report a problemFND-2854480705
06HumanRandomized controlled trialEfficacy outcome
In patients with controlled rheumatoid arthritis, lumbar spine BMD improved in the teriparatide group.
In plain wordsIn patients with controlled rheumatoid arthritis, lower spine bone density improved during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 12
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 yearAs given in this study (human).
Source sentences
Summary
Bone mineral density improved at the femoral neck and lumbar spine in the teriparatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
We conducted a randomized controlled trial in 24 patients with erosive RA, osteopenia, and disease activity controlled by TNFi treatment for at least 3 months.
Summary · context
Half were randomized to receive teriparatide for 1 year and the others constituted a wait-list control group.
Report a problemFND-2854480706

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01400516

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Brigham and Women's Hospitaln = 26Aug 2011 to 28 Jul 2016

Rheumatoid Arthritis

Trial page ClinicalTrials.govUpdated 11 Apr 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.